Roche, J&J strike $3.3B in protein degrader deals on same day

Pharma Giants Bet Big on Protein Degrader Drug Candidates

Monday brought a triple dose of news underscoring Big Pharma’s growing conviction in targeted protein degradation, a therapeutic approach that commandeers the body’s own cellular recycling machinery to destroy disease-causing proteins rather than simply blocking them. Roche announced a collaboration with Nurix Therapeutics worth up to $2.3 billion, Johnson & Johnson agreed to acquire Firefly Bio for $1 billion in cash, and Amphista Therapeutics disclosed FDA clearance of its first investigational new drug application.

Roche and Nurix: A $2.3 Billion BTK Degrader Alliance

Under the exclusive licensing and collaboration agreement announced Monday, Nurix will receive an upfront cash payment of $700 million and is eligible for development, regulatory, and sales milestones bringing the potential total deal value to $2.3 billion. The partnership centers on bexobrutideg (NX-5948), an oral, brain-penetrant degrader of Bruton’s tyrosine kinase, or BTK, a protein central to B-cell cancers and autoimmune diseases.roche

Roche will bear 60 percent of development costs, with the two companies sharing U.S. profits equally and co-commercializing the drug across all indications in the United States. Outside the U.S., Roche will lead commercialization and pay Nurix royalties ranging from the low to high teens. A Phase 3 trial in chronic lymphocytic leukemia is planned to begin this summer, with additional Phase 2 studies targeting multiple sclerosis and chronic spontaneous urticaria. The deal is expected to close in the third quarter of 2026.yahoo

J&J Acquires Firefly Bio for $1 Billion

Johnson & Johnson said Monday it has entered a definitive agreement to acquire Firefly Bio for $1 billion in cash, gaining access to the startup’s proprietary Firelink degrader antibody conjugate platform. The technology is designed to address KRAS-driven cancers, a class of tumors that has long been considered among the hardest to treat. According to J&J’s press release, the transaction is expected to close later this year, subject to regulatory approvals.biopharmadive

Amphista Clears FDA Hurdle

Separately, Cambridge-based Amphista Therapeutics announced that the FDA cleared its IND application for AMX-883, described as the only BRD9 degrader currently in development. The drug uses Amphista’s proprietary DCAF16-dependent “Targeted Glue” mechanism rather than the cereblon-based approach common to earlier degraders. A Phase 1 dose-escalation trial enrolling patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome is expected to begin in the second half of 2026.businessinsider

The convergence of three deals in a single day reflects a broader industry thesis: that protein degraders can overcome resistance mutations that limit conventional inhibitor drugs and unlock targets once deemed undruggable. As Roche noted in its announcement, bexobrutideg’s mechanism of eliminating the BTK protein entirely could address resistance seen with current standard-of-care BTK inhibitors.roche